Reddit Posts
Mentions
It’s wild how a ticker like $OSTX can get flooded with upvotes off a press release no one’s actually talking about. Patent news is cool, sure—but how many biotech plays have patents and still go nowhere? Let’s not act like this guarantees clinical success or revenue. Meanwhile, $AITX is cutting over $1.2M in waste, tightening ops, and inching toward positive cash flow—real moves, not just paper IP hype.
Can someone explain the situation of OSTX?
I really don't understand.. Why is OSTX falling? Is it because of short selling?
OSTX volume doesn't stick...
OSTX [OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040](https://finance.yahoo.com/news/os-therapies-announces-issuance-u-124500681.html)
OSTX - halted, pending news. Watch it
Im also gonna once again tell yall to pay attention to OSTX. It's all there. You're a few weeks late, but the potential remains. Do your own research, but there are several posts on the penny stock page and in the lounge about it.
Where's OSTX man? Thanks for the call
Once again shouting out OSTX. The fundamentals and positive upcoming catalysts are all there. And if you don't care about any of that, just look at the chart. It's been climbing non stop and the volume is finally starting to increase
Took a shot in the dark, put my money in OSTX
Everyone's foaming at the mouth over these pump and dump gambles but let me put you onto OSTX, a company with solid fundamentals, no danger of delisting/reverse splitting/bankruptcy, huge upside potential according to analysts, and a number of positive upcoming catalysts. Not to mention it's been climbing steadily over the last 2 weeks with larger jumps over the last couple days as people are starting to take notice. The only thing this stock lacks is volume and that won't be for long.
I've been calling out OSTX for months. It's been nothing but positive news for this company but there just isn't much trade volume yet. It's way undervalued for what it is and just like at the end of the year, I'm expecting a short term pop to at least $4 in the next couple months, and long term higher than that
Appreciate the TA breakdown but from a biotech perspective, I’d be cautious interpreting OSTX’s compression as a signal of fundamental strength. OS Therapies is still extremely early-stage… and the Advaxtis acquisition is mostly narrative at this point. there’s no clinically de-risked asset in play yet.The FDA meeting they “secured” isn’t a milestone it’s standard protocol, and no trial is currently enrolling. Pipeline visibility is limited, and there’s zero indication of platform scalability or strategic differentiation in their data. So even with a tight float, the underlying story lacks the biological credibility that would justify sustained re-pricing.seen this setup before,retail volume pushes it through $1.70, then insiders or early holders fade into the rally. The burden of proof is on the pipeline now, not the tape.
You’ve moved on from $ACTU? This is only your 6th $OSTX post now.
OSTX: from obscurity to 'encouraging signs' overnight. Acquisition? Check. FDA meeting? Check. Now, will it moon or crater? Place your bets, folks. #BiotechRoulette
80% OSTX and 20% NAK OS Therapeutics imo is severely undervalued atm and going under the radar. They've got very positive study results and pending FDA approval.
OSTX OS Therapies (NYSE-A: OSTX) has secured a presentation slot at the MIB Agents Factor Osteosarcoma Conference in Salt Lake City (June 26-28, 2025) to showcase data from their Phase 2b clinical trial of OST-HER2. The trial focuses on preventing recurrent, fully resected, lung metastatic osteosarcoma. The company will present comparative data with a regulatorily compliant synthetic control group, which will be used for their upcoming FDA Biologics License Application (BLA). The company plans to submit the BLA in Q2 2025, with potential approval expected in Q4 2025. OST-HER2 has received multiple regulatory designations including: Rare & Pediatric Disease Designation from FDA Fast Track and Orphan Drug Designations from both FDA and EMA If approved before September 30, 2026, the company will receive a Priority Review Voucher (PRV), which can be sold to third parties. For reference, the most recent PRV was sold by Zevra for $150 million.
OSTX is toast bro I got screwed on that play
I put the rest of what I’m willing to deposit in OSTX today. Good luck this week fellas
OSTX seems to be a good long term play
OSTX is the new play. Long term potential
Check out OSTX. Company just secured patent into 2040 in a billion dollar cancer drug sob-market and moved up in Premarket[https://www.stocktitan.net/news/OSTX/os-therapies-receives-patent-notice-of-allowance-from-u-s-patent-0gr92vc4anzz.html](https://www.stocktitan.net/news/OSTX/os-therapies-receives-patent-notice-of-allowance-from-u-s-patent-0gr92vc4anzz.html)
OSTX because of good news
Interesting picks! OSTX has some solid potential with that BLA submission. MBRX's big jump caught attention, could be a good one to track.
I traded OSTX Friday. Got in and out around 2.46 at break even. I was hoping for it to climb but it never could break 2.64, gave a few chances but got out even. Glad I got out before the weekend since it went down to 2.07 after market.
OSTX is my next pal to invest in
Hey lads, just wanted to draw attention to a company I've been interested in. It's OSTX - a biotech company that's been focusing on developing advanced therapies for osteosarcoma. While it's a smaller market, progress has been insane due to much research done on osteosarcoma through dogs. The company also generated statistically significant results in its clinical trial 2b of OST-HER2 for lung metastatic osteosarcoma. Recently, they've strategically acquired programs from another company, with clever financing. Here's the recent news: [https://www.stocktitan.net/news/OSTX/os-therapies-agrees-to-acquire-all-listeria-monotygenes-based-immuno-tzmyae911h6y.html](https://www.stocktitan.net/news/OSTX/os-therapies-agrees-to-acquire-all-listeria-monotygenes-based-immuno-tzmyae911h6y.html) . I purchased shares today at $1.95. It's been in a downtrend, further done by a dilution required to immediately pay for the acquisition. However, I see a reversal coming and so do several analysts who are quite optimistic about this company. Feel free to critique or discuss this matter with me and/or each other.
Okay can anyone take a look at OSTX and tell mě what the fuck is going on with that stock on 0 news mind you
Bought more CKPT today Its up 5%, issue is the stock I sold to buy it OSTX Is up 80 FUCKING PERCENT ON NO NEWS, FUCK ME 
What is the story on OSTX? They have been increasing significantly in recent days, and I still can’t really find any news on it.
Consider stocks near consolidation or recent dips; look for undervalued setups like SGMT or OSTX.
OSTX volatile; watch $3.00 support and $3.50 resistance closely.
Woo Woo I’m in OSTX at $2.13 since 12/04 and am up 51.18%!!!
Up 90% on OSTX hold or sell? 
Should have went with OSTX :D nearly 100% up since 12.2.
I heard about OSTX on here months ago but no ones's really been talking about it since. Great company working on treatment for various types of cancer treatments with a couple studies approaching late phase results. Low float, and mooned this week without any public news. I got in around 3$, hodling till atleast 7$
Your post with title "Anybody saw the movement from last couple of days for OSTX? any news might coming? " has been automatically removed from r/PennyStocks for being low-effort/spam. (Low word count) probably by u/automod *I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/pennystocks) if you have any questions or concerns.*
OSTX's pipeline looks strong. Their [OST-HER2 immunotherapy just finished Phase 2b trials with 41 patients](https://finance.yahoo.com/news/os-therapies-reports-third-quarter-144700839.html) and results coming in December. Not just another biotech - they already have conditional USDA approval for canine osteosarcoma treatment. Big potential revenue streams lined up. Out-licensing deals for canine OS ($15M+), human OS ($100M+), and their tADC platform ($20-80M). Plus a [priority review voucher worth $100-110M](https://finance.yahoo.com/news/join-os-therapies-exclusive-live-125100836.html) once they get FDA approval. They just [added two pharma veterans to the board](https://finance.yahoo.com/news/os-therapies-appoints-two-bio-204400770.html) - McKean Dieser from UCB and Jarry who worked at Bristol-Myers Squibb. Shows they're serious about commercialization. The chart looks ready to break out. Volume's picking up too. December data readout will be huge.
OSTX pumping today https://preview.redd.it/y5mqgjpre26e1.png?width=702&format=png&auto=webp&s=0fec25b980991e1e929e0c3fc77ce26f335552de 
Did Martin Shkreli analyze OSTX?
Haven't checked on OSTX in a minute. Been waiting for those trial results with the OST-HER2
Despite potential regulatory challenges, the biotech sector's innovation and growth prospects remain strong, with companies like OSTX and CTXR well-positioned...
Whole post is about broader market sentiment and "my girlfriend is a biomedical engineer". Nothing about your post really differentiates OSTX from any other early phase bios in the oncology space. Yes ADCs seem to have promise but there is an ocean to cross before regulatory approval and commercialisation. My personal feeling is that the stock will drop all the while.
Definitely bullish on OSTX. Im in for about 1k shares so far and looking to slowly add more